In 1922, Werner Schultz1 described a syndrome which ultimately came to be known as agranulocytosis. At first but a few cases were recognized, but between 1929 and 1934 a large number were reported. About this time (1931) Kracke2 noted that the sudden appearance and growing number of cases of agranulocytosis corresponded with the introduction of certain coal-tar derivatives as therapeutic agents. The disorder was especially common in the countries in which such drugs were in great use, and those affected were chiefly women of good economic status as well as nurses and other medical workers to whom these drugs were easily accessible. Shortly afterward several reports appeared* which incriminated aminopyrine (Pyramidon) as the offending drug. After 1934 the number of cases of agranulocytosis began to decrease. This coincided with the reduced sales of aminopyrine following reports of its injurious effects.5Later, however, as new drugs
WINTROBE MM, CARTWRIGHT GE. Blood Disorders Caused by Drug Sensitivity. AMA Arch Intern Med. 1956;98(5):559–566. doi:10.1001/archinte.1956.00250290019004
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: